Surprisingly, we observed a trend toward lower ELF concentrations of IL-6 in COVID-19 patients compared with non-COVID-19 ARDS patients (p = 0.11), thus challenging the interest of anti-IL-6 therapies in severe COVID-19 pneumonia. Here, IL6 is linked to acute respiratory distress syndrome.